Asuragen, Inc. Launches The Quantidex™ DNA Assay To Improve The Accuracy Of Next-Generation Sequencing
AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc. announced today the launch of the Quantidex™ DNA Assay at the Association for Molecular Pathology (AMP) Annual Meeting in National Harbor, MD. This product quantifies absolute copy numbers of genomic DNA, flags PCR inhibitors from the sample, and reports functional DNA quality from challenging specimens such as FFPE tumor biopsies using the QFI™ Score to increase the reliability and accuracy of next-generation sequencing (NGS) assays.
A key problem for NGS assays of challenging clinical samples is that the two methods that are most commonly used by laboratories to quantify DNA, spectrophotometry and fluorescence-dye binding assays, may not reliably report the DNA that is actionable in target enrichment assays. This limitation is particularly problematic for FFPE and FNA cancer specimens that suffer from chemical modifications, fragmentation, or low DNA yields that impact DNA quality and quantity. Spectrophotometry is insensitive to DNA quality, and dye-binding assays fail to discriminate among the low-quality samples that are commonly observed with FFPE biopsies. The disconnect between DNA quantification and DNA actionability can lead to failed NGS runs and delayed turnaround-times, or, worse, false-positive and -negative calls. The Quantidex™ DNA assay reports amplifiable DNA, rather than bulk DNA, and predicts performance in targeted NGS assays that rely on similar enzymatic methods to generate target-enriched, sequenceable libraries.
Help employers find you! Check out all the jobs and post your resume.
A key problem for NGS assays of challenging clinical samples is that the two methods that are most commonly used by laboratories to quantify DNA, spectrophotometry and fluorescence-dye binding assays, may not reliably report the DNA that is actionable in target enrichment assays. This limitation is particularly problematic for FFPE and FNA cancer specimens that suffer from chemical modifications, fragmentation, or low DNA yields that impact DNA quality and quantity. Spectrophotometry is insensitive to DNA quality, and dye-binding assays fail to discriminate among the low-quality samples that are commonly observed with FFPE biopsies. The disconnect between DNA quantification and DNA actionability can lead to failed NGS runs and delayed turnaround-times, or, worse, false-positive and -negative calls. The Quantidex™ DNA assay reports amplifiable DNA, rather than bulk DNA, and predicts performance in targeted NGS assays that rely on similar enzymatic methods to generate target-enriched, sequenceable libraries.
Help employers find you! Check out all the jobs and post your resume.